CAJ | 학술논문

目的：观察洛铂联合替吉奥治疗晚期食管癌的疗效及安全性。方法32例晚期食管癌患者均采用洛铂联合替吉奥化疗。结果全组32例晚期食管癌患者中，CR 1例，PR 9例，SD 10例，PD 12例，有效率为31.25%，疾病控制率为62.50%。主要毒副反应为骨髓抑制，其中Ⅲ、Ⅳ度白细胞减少发生率43.75%（14/32），Ⅲ、Ⅳ度血小板减少发生率21.88%（7/32），Ⅲ、Ⅳ度贫血发生率9.38%（3/32）。结论洛铂联合替吉奥晚期食管癌的疗效较好，毒副反应可耐受。
목적：관찰락박연합체길오치료만기식관암적료효급안전성。방법32례만기식관암환자균채용락박연합체길오화료。결과전조32례만기식관암환자중，CR 1례，PR 9례，SD 10례，PD 12례，유효솔위31.25%，질병공제솔위62.50%。주요독부반응위골수억제，기중Ⅲ、Ⅳ도백세포감소발생솔43.75%（14/32），Ⅲ、Ⅳ도혈소판감소발생솔21.88%（7/32），Ⅲ、Ⅳ도빈혈발생솔9.38%（3/32）。결론락박연합체길오만기식관암적료효교호，독부반응가내수。
Objective To evaluate the efficacy and safety of lobaplatin plus S-1 for patients with advanced e-sophageal carcinoma. Methods Thirty-two patients with advanced esophageal carcinoma received lobaplatin plus S-1 chemotherapy. Results Of the 32 patients,CR was observed in the 1 patient,PR in the 9 patients,SD in the 10 patients,PD in the 12 patients,the overall response rate was 31. 25% ,and the disease control rate was 62. 50% . The main toxicities were marrow depression,the incidence of grade Ⅲ and Ⅳ neutropenia was 43. 75% ,that of grade Ⅲ and Ⅳ thrombocytopenia was 21. 88% ,that of grade Ⅲ and Ⅳ anemia was 9. 38% . Conclusion Loba-platin plus S-1 chemotherapy is effect and safe for patients with advanced esophageal carcinoma.